Inhaled Delivery of Next Generation Cardiovascular Treatments via Nano‑in‑Micro Technology

NanoPhoria Bioscience is a preclinical-stage biotech company pioneering the next generation of cardiovascular treatments through an innovative inhaled, Nano-in-Micro delivery platform. Our mission is to transform the way therapeutic peptides and RNAs are delivered, enabling precise, tissue-directed treatment for complex cardiovascular conditions.

HFrEF UNMET DEMAND

30m
patients

An estimated 30m patients worldwide suffer from Heart Failure with Reduced Ejection Fraction

Bahira Shahimet al. 2023

>60%
mortality rate

Despite advances, 5-year mortalityrate still stands at over 60% and has been increasing in recent years

W.J. Quah et al, 2022

will cost
$70bn

Heart failure is set to cost the US healthcare system $70bn by 2030

Chen Wei et al. 202

THERAPEUTIC FOCUS

Advancing Care for Patients Suffering from Heart Failure with Reduced Ejection Fraction (HFrEF)

Learn more...

PLATFORM

At the core of our delivery technology is a proprietary nano-in-micro platform built on inorganic Calcium Phosphate (CaP) nanoparticles

Learn more...